2013 Canadian Spinal Cord Conference
2013 Conférence Canadienne sur la Moelle Épinière
April 21 to 23, 2013 — Halifax Marriott Harbourfront, Halifax, Nova Scotia
Abstract Submission Information

Tips and Information about the Submission of your Abstract

The deadline for submitting abstracts is March 8, 2013.

The abstract template

You will find a downloadable abstract template at the end of this section. Please read through the following instructions before downloading and completing this document or download a PDF version of these instructions here.

Instructions for filling in the abstract template:

1. Indicate which of the following tentative sessions would be appropriate for your abstract:

  • Spinal cord development, physiology, and plasticity
  • Pathophysiology of spinal cord injury
  • Acute interventions in and clinical assessment of SCI: animal models and humans
  • Innovations in rehabilitation
  • Towards clinic trials: bioethics and trial design

2. Indicate your preferences for session:

  • 1st choice of session, and
  • 2nd choice of session

3. Indicate your preferred presentation format:

Authors may select from two presentation formats when submitting an abstract: “platform preferred” or “poster only.” The “platform preferred” selection indicates that you would like a platform session, but will accept a poster format if necessary. Marking “poster only” indicates that you would not like to be considered for a platform session.

4. Complete your abstract in a format similar to that required by the Society for Neuroscience (SfN).

The following points have been adapted from the SfN:

Abstract

The abstract should begin with the Title, Authors and Affilation (institution and department), and end with a statement about conflicts of interest, should there be any.

Title

Please write your title in sentence case (first letter is capitalized; remaining letters are lower case). Do not bold or italicize your full title.

Author

List all authors who contributed to the work discussed in the abstract. The presenting author must be listed in the first author slot of the list. Authors must disclose their sources of contributed support (commercial, public, or private foundation grants).This information will emphasize the importance of the organizations that sponsor research.

Summary of the research

The summary of your research should be no more than 250 words. Work presented in abstracts must conform with applicable policies and principles for experimental procedures. The member who submits/sponsors the abstract is responsible for ensuring that work presented in the abstract is in accord with the SfN's Policies on the Use of Animals and Humans in Neuroscience Research, as well as (where applicable) the Declaration of Helsinki.

The abstract should state the study’s objective, briefly describe the methods used, summarize the results obtained, and state the conclusions. It is not satisfactory to say, “The results will be discussed.” Abstracts should emphasize the significance of results and general principles rather than ordinary methods and procedures. When experimental animals are used, the species should be stated. When relevant, state the sex of experimental animals and humans, and whether males and females were analyzed by sex. Use standard abbreviations for units of measure. Other abbreviations should be fully spelled out on first mention, followed by the abbreviation in parentheses.

Conflicts of interest

Authors must signify whether there may be a real or perceived conflict of interest. Any potential for financial gain that may be derived from reported work may constitute a potential conflict of interest. Financial contributions from commercial sponsors to the work being reported may be perceived as a potential conflict of interest and should be clearly acknowledged. Authors should ensure that no contractual relations or proprietary considerations exist that restrict dissemination of their findings. It is the author’s responsibility to report any real or perceived financial conflict of interest.

In general, disclosure is required in any case in which an individual or company stands to benefit financially from research performed. Consequently, the central criterion of this policy places the onus for disclosure on each author to indicate any benefit to an individual or company that may derive from any and all relationships that may potentially lead to financial reward.

Examples of conflicts of interest

The following list of examples is not all-encompassing. For more information on conflict of interest, see Guidelines for Responsible Conduct Regarding Scientific Communication.

  • Author (or first-degree relative) holds an equity position in a company that produces a product or service related to the work being reported.
  • Author has a consultative relationship (including as a member of a scientific advisory board) with a company that produces a product or service related to the work being reported.
  • Author's research is funded by a company that produces a product or service related to the work being reported.
  • Author founded a company that produces a product or service related to the work being reported.
  • Author receives royalties from a company that produces a product or service related to the work being reported.
  • Patent or license related to the work being reported is held by the author and/or a university without direct corporate involvement at the time.
  • Author (or first-degree relative) derives a real or potential royalty stream through university arrangements and/or directly from a company that produces a product or service related to the work being reported.
  • Real or potential royalty streams are generated from multiple sources
Download template in DOC (MS Word) format

Fax 902-473-6852 or email your completed abstract to: This e-mail address is being protected from spambots. You need JavaScript enabled to view it , by March 8, 2013.

 

Dalhousie University AMAP Boston Scientific Brain Repair Centre ERRSM U of A Medtronic QEII Rick Hansen Zeiss

Powered by Bridgewater Media Services.